Ticker Symbol: RLMD
Relmada Therapeutics Inc
$21.87 - 20-11-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001553643
Company Profile
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Its experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.
Sector: Manufacturing
Industry: Sporting and Athletic Goods Manufacturing
Standard Industrial Classification Code (SIC code): 3949
Address: 880 3rd Ave Fl 12
Website: www.relmada.com
CEO: Sergio Traversa
Tags:
- Pharmaceuticals: Major
- Health Technology
- Manufacturing
- Sporting and Athletic Goods Manufacturing
Pricing
Last Updated: October 13, 2023 03:00 PM EST
Previous Close: $3.10
Change:
-$0.10
(
-3.12%)
Days Range: $3.03 - $3.25
Beta: 1.03
52wk. High: $7.33
52wk. Low: $1.81
Ytd. Change -14.30%
50 Day Moving Average: $3.19
200 Day Moving Average: $2.91
Shares Outstanding: 30099203
Valuation
Market Cap: 9.3B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A